These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 38518602)

  • 1. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
    Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
    Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
    Jiang P; Sun N; Yang W; Xiao L; Zhou L; Gu B; Li Y; Li L; Li J; Li X; Li W; Guo L
    Diabetes Obes Metab; 2023 Nov; 25(11):3356-3365. PubMed ID: 37580307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
    Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
    J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
    Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A GLP-1/glucagon (GCG)/CCK
    Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
    Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
    Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
    Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity.
    Li Q; Yang Q; Han J; Liu X; Fu J; Yin J
    Chin J Nat Med; 2022 Nov; 20(11):863-872. PubMed ID: 36427920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
    Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
    Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists.
    Jiang N; Jing L; Li Q; Su S; Yang Q; Zhou F; Chen X; Han J; Tang C; Tang W
    Eur J Med Chem; 2021 Feb; 212():113118. PubMed ID: 33422984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
    Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
    Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.